{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T06:05:56Z","timestamp":1668665156367},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1055\/a-1810-9199","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T23:49:09Z","timestamp":1668642549000},"page":"1522-1530","source":"Crossref","is-referenced-by-count":0,"title":["Kardiale Amyloidose \u2013 wichtige Differenzialdiagnose bei Herzinsuffizienz"],"prefix":"10.1055","volume":"147","author":[{"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Steinhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction","volume":"6","author":"O F AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"A D Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","article-title":"Amyloidosis in Heart Failure","volume":"16","author":"S Ihne","year":"2019","journal-title":"Curr Heart Fail Rep"},{"issue":"10","key":"ref4","first-page":"159","article-title":"Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease","volume":"117","author":"S Ihne","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"01","key":"ref5","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"R A Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"17","key":"ref6","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"A D Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2016.05.020","article-title":"Transthyretin Amyloidosis: A \u201cZebra\u201d of Many Stripes","volume":"68","author":"M J Semigran","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"ref8","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"J D Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"P Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"A Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"S V Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update","volume":"96","author":"E Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"36","key":"ref13","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"T A McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"32","key":"ref14","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"A D\u2019Souza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"E Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-021-00510-7","article-title":"Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib","volume":"11","author":"S Ravichandran","year":"2021","journal-title":"Blood Cancer J"},{"issue":"36","key":"ref17","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"G Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"ref18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"R Manwani","year":"2019","journal-title":"Blood"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"M S Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"M D Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"D Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"S D Solomon","year":"2019","journal-title":"Circulation"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13023-017-0642-0","article-title":"Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever","volume":"12","author":"S Ugurlu","year":"2017","journal-title":"Orphanet J Rare Dis"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1810-9199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T23:49:54Z","timestamp":1668642594000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1810-9199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,11,16]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1810-9199","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}